Literature DB >> 29206660

Recent developments in systemic lupus erythematosus pathogenesis and applications for therapy.

Mindy S Lo1,2, George C Tsokos3,4.   

Abstract

PURPOSE OF REVIEW: Systemic lupus erythematosus (SLE) pathogenesis is complex. Aberrancies of immune function that previously were described but not well understood are now becoming better characterized, in part through recognition of monogenic cases of lupus-like disease. RECENT
FINDINGS: We highlight here recent descriptions of metabolic dysfunction, cytokine dysregulation, signaling defects, and DNA damage pathways in SLE. Specifically, we review the effects of signaling abnormalities in mammalian target of rapamycin, Rho kinase, Bruton's tyrosine kinase, and Ras pathways. The importance of DNA damage sensing and repair pathways, and their influence on the overproduction of type I interferon in SLE are also reviewed.
SUMMARY: Recent findings in SLE pathogenesis expand on previous understandings of broad immune dysfunction. These findings have clinical applications, as the dysregulated pathways described here can be targeted by existing and preclinical therapies.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29206660      PMCID: PMC6050980          DOI: 10.1097/BOR.0000000000000474

Source DB:  PubMed          Journal:  Curr Opin Rheumatol        ISSN: 1040-8711            Impact factor:   5.006


  64 in total

1.  Mechanistic target of rapamycin complex 1 expands Th17 and IL-4+ CD4-CD8- double-negative T cells and contracts regulatory T cells in systemic lupus erythematosus.

Authors:  Hiroshi Kato; Andras Perl
Journal:  J Immunol       Date:  2014-03-28       Impact factor: 5.422

2.  The importance of considering monogenic causes of autoimmunity: A somatic mutation in KRAS causing pediatric Rosai-Dorfman syndrome and systemic lupus erythematosus.

Authors:  Robert J Ragotte; Anita Dhanrajani; Julian Pleydell-Pearce; Kate L Del Bel; Maja Tarailo-Graovac; Clara van Karnebeek; Jefferson Terry; Christof Senger; Margaret L McKinnon; Michael Seear; Julie S Prendiville; Lori B Tucker; Kristin Houghton; David A Cabral; Jaime Guzman; Ross E Petty; Kelly L Brown; Jenny Tekano; John Wu; Kimberly A Morishita; Stuart E Turvey
Journal:  Clin Immunol       Date:  2016-12-31       Impact factor: 3.969

Review 3.  T cell signaling abnormalities contribute to aberrant immune cell function and autoimmunity.

Authors:  Vaishali R Moulton; George C Tsokos
Journal:  J Clin Invest       Date:  2015-05-11       Impact factor: 14.808

4.  Familial chilblain lupus due to a gain-of-function mutation in STING.

Authors:  Nadja König; Christoph Fiehn; Christine Wolf; Max Schuster; Emanuel Cura Costa; Victoria Tüngler; Hugo Ariel Alvarez; Osvaldo Chara; Kerstin Engel; Raphaela Goldbach-Mansky; Claudia Günther; Min Ae Lee-Kirsch
Journal:  Ann Rheum Dis       Date:  2016-08-26       Impact factor: 19.103

5.  ATP-binding cassette transporter G1 negatively regulates thymocyte and peripheral lymphocyte proliferation.

Authors:  Allison J Armstrong; Abraham K Gebre; John S Parks; Catherine C Hedrick
Journal:  J Immunol       Date:  2009-11-30       Impact factor: 5.422

6.  Activation of mammalian target of rapamycin controls the loss of TCRzeta in lupus T cells through HRES-1/Rab4-regulated lysosomal degradation.

Authors:  David R Fernandez; Tiffany Telarico; Eduardo Bonilla; Qing Li; Sanjay Banerjee; Frank A Middleton; Paul E Phillips; Mary K Crow; Stefanie Oess; Werner Muller-Esterl; Andras Perl
Journal:  J Immunol       Date:  2009-02-15       Impact factor: 5.422

7.  Protein phosphatase 2A enables expression of interleukin 17 (IL-17) through chromatin remodeling.

Authors:  Sokratis A Apostolidis; Thomas Rauen; Christian M Hedrich; George C Tsokos; José C Crispín
Journal:  J Biol Chem       Date:  2013-08-05       Impact factor: 5.157

8.  Trex1 prevents cell-intrinsic initiation of autoimmunity.

Authors:  Daniel B Stetson; Joan S Ko; Thierry Heidmann; Ruslan Medzhitov
Journal:  Cell       Date:  2008-08-22       Impact factor: 41.582

9.  Characterization of human disease phenotypes associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, ADAR, and IFIH1.

Authors:  Yanick J Crow; Diana S Chase; Johanna Lowenstein Schmidt; Marcin Szynkiewicz; Gabriella M A Forte; Hannah L Gornall; Anthony Oojageer; Beverley Anderson; Amy Pizzino; Guy Helman; Mohamed S Abdel-Hamid; Ghada M Abdel-Salam; Sam Ackroyd; Alec Aeby; Guillermo Agosta; Catherine Albin; Stavit Allon-Shalev; Montse Arellano; Giada Ariaudo; Vijay Aswani; Riyana Babul-Hirji; Eileen M Baildam; Nadia Bahi-Buisson; Kathryn M Bailey; Christine Barnerias; Magalie Barth; Roberta Battini; Michael W Beresford; Geneviève Bernard; Marika Bianchi; Thierry Billette de Villemeur; Edward M Blair; Miriam Bloom; Alberto B Burlina; Maria Luisa Carpanelli; Daniel R Carvalho; Manuel Castro-Gago; Anna Cavallini; Cristina Cereda; Kate E Chandler; David A Chitayat; Abigail E Collins; Concepcion Sierra Corcoles; Nuno J V Cordeiro; Giovanni Crichiutti; Lyvia Dabydeen; Russell C Dale; Stefano D'Arrigo; Christian G E L De Goede; Corinne De Laet; Liesbeth M H De Waele; Ines Denzler; Isabelle Desguerre; Koenraad Devriendt; Maja Di Rocco; Michael C Fahey; Elisa Fazzi; Colin D Ferrie; António Figueiredo; Blanca Gener; Cyril Goizet; Nirmala R Gowrinathan; Kalpana Gowrishankar; Donncha Hanrahan; Bertrand Isidor; Bülent Kara; Nasaim Khan; Mary D King; Edwin P Kirk; Ram Kumar; Lieven Lagae; Pierre Landrieu; Heinz Lauffer; Vincent Laugel; Roberta La Piana; Ming J Lim; Jean-Pierre S-M Lin; Tarja Linnankivi; Mark T Mackay; Daphna R Marom; Charles Marques Lourenço; Shane A McKee; Isabella Moroni; Jenny E V Morton; Marie-Laure Moutard; Kevin Murray; Rima Nabbout; Sheela Nampoothiri; Noemi Nunez-Enamorado; Patrick J Oades; Ivana Olivieri; John R Ostergaard; Belén Pérez-Dueñas; Julie S Prendiville; Venkateswaran Ramesh; Magnhild Rasmussen; Luc Régal; Federica Ricci; Marlène Rio; Diana Rodriguez; Agathe Roubertie; Elisabetta Salvatici; Karin A Segers; Gyanranjan P Sinha; Doriette Soler; Ronen Spiegel; Tommy I Stödberg; Rachel Straussberg; Kathryn J Swoboda; Mohnish Suri; Uta Tacke; Tiong Y Tan; Johann te Water Naude; Keng Wee Teik; Maya Mary Thomas; Marianne Till; Davide Tonduti; Enza Maria Valente; Rudy Noel Van Coster; Marjo S van der Knaap; Grace Vassallo; Raymon Vijzelaar; Julie Vogt; Geoffrey B Wallace; Evangeline Wassmer; Hannah J Webb; William P Whitehouse; Robyn N Whitney; Maha S Zaki; Sameer M Zuberi; John H Livingston; Flore Rozenberg; Pierre Lebon; Adeline Vanderver; Simona Orcesi; Gillian I Rice
Journal:  Am J Med Genet A       Date:  2015-01-16       Impact factor: 2.802

10.  HM71224, a selective Bruton's tyrosine kinase inhibitor, attenuates the development of murine lupus.

Authors:  Yu-Yon Kim; Ki Tae Park; Sun Young Jang; Kyu Hang Lee; Joo-Yun Byun; Kwee Hyun Suh; Young-Mi Lee; Young Hoon Kim; Kwang Woo Hwang
Journal:  Arthritis Res Ther       Date:  2017-09-26       Impact factor: 5.156

View more
  14 in total

1.  Splicing factor SRSF1 controls T cell hyperactivity and systemic autoimmunity.

Authors:  Takayuki Katsuyama; Hao Li; Denis Comte; George C Tsokos; Vaishali R Moulton
Journal:  J Clin Invest       Date:  2019-12-02       Impact factor: 14.808

2.  Resolution of inflammation: from basic concepts to clinical application.

Authors:  Markus F Neurath
Journal:  Semin Immunopathol       Date:  2019-11       Impact factor: 9.623

3.  Lupus Susceptibility Loci Predispose Mice to Clonal Lymphocytic Responses and Myeloid Expansion.

Authors:  Elliot H Akama-Garren; Michael C Carroll
Journal:  J Immunol       Date:  2022-04-27       Impact factor: 5.426

4.  Splicing factor SRSF1 limits IFN-γ production via RhoH and ameliorates experimental nephritis.

Authors:  Takayuki Katsuyama; Hao Li; Suzanne M Krishfield; Vasileios C Kyttaris; Vaishali R Moulton
Journal:  Rheumatology (Oxford)       Date:  2021-01-05       Impact factor: 7.580

5.  Inositol-Requiring Enzyme 1α-Mediated Synthesis of Monounsaturated Fatty Acids as a Driver of B Cell Differentiation and Lupus-like Autoimmune Disease.

Authors:  Yana Zhang; Ming Gui; Yajun Wang; Nikita Mani; Shuvam Chaudhuri; Beixue Gao; Huabin Li; Yashpal S Kanwar; Sarah A Lewis; Sabrina N Dumas; James M Ntambi; Kezhong Zhang; Deyu Fang
Journal:  Arthritis Rheumatol       Date:  2021-11-02       Impact factor: 10.995

6.  DNA glycosylase deficiency leads to decreased severity of lupus in the Polb-Y265C mouse model.

Authors:  Sesha L Paluri; Matthew Burak; Alireza G Senejani; Madison Levinson; Tania Rahim; Kaylyn Clairmont; Michael Kashgarian; Isabel Alvarado-Cruz; Rithy Meas; Marina Cardó-Vila; Caroline Zeiss; Stephen Maher; Alfred L M Bothwell; Erdem Coskun; Melis Kant; Pawel Jaruga; Miral Dizdaroglu; R Stephen Lloyd; Joann B Sweasy
Journal:  DNA Repair (Amst)       Date:  2021-06-24

7.  Downregulation of SLC7A7 Triggers an Inflammatory Phenotype in Human Macrophages and Airway Epithelial Cells.

Authors:  Bianca Maria Rotoli; Amelia Barilli; Rossana Visigalli; Filippo Ingoglia; Marco Milioli; Maria Di Lascia; Benedetta Riccardi; Paola Puccini; Valeria Dall'Asta
Journal:  Front Immunol       Date:  2018-03-19       Impact factor: 7.561

Review 8.  Targeting Regulatory T Cells to Treat Patients With Systemic Lupus Erythematosus.

Authors:  Masayuki Mizui; George C Tsokos
Journal:  Front Immunol       Date:  2018-04-17       Impact factor: 7.561

Review 9.  Monogenic Lupus: A Developing Paradigm of Disease.

Authors:  Jessie M Alperin; Lourdes Ortiz-Fernández; Amr H Sawalha
Journal:  Front Immunol       Date:  2018-10-30       Impact factor: 7.561

10.  High genetic risk score is associated with early disease onset, damage accrual and decreased survival in systemic lupus erythematosus.

Authors:  Sarah Reid; Andrei Alexsson; Martina Frodlund; David Morris; Johanna K Sandling; Karin Bolin; Elisabet Svenungsson; Andreas Jönsen; Christine Bengtsson; Iva Gunnarsson; Vera Illescas Rodriguez; Anders Bengtsson; Sabine Arve; Solbritt Rantapää-Dahlqvist; Maija-Leena Eloranta; Ann-Christine Syvänen; Christopher Sjöwall; Timothy James Vyse; Lars Rönnblom; Dag Leonard
Journal:  Ann Rheum Dis       Date:  2019-12-11       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.